Deucravacitinib (also known as IBI-10090) is a novel small molecule therapy that is being studied as a potential treatment for certain cancers. It is an oral, once-daily, selective Janus kinase (JAK) 1 and JAK2 inhibitor that works by inhibiting the activity of JAK proteins, which can play a role in cancer growth and progression. Deucravacitinib is being investigated in clinical trials for the treatment of solid tumors and hematological malignancies.
Deucravacitinib, sold under the brand name Sotyktu, is a medication specifically used for treating moderate-to-severe plaque psoriasis in adults. Here's a breakdown of its key aspects:
Function:
- Deucravacitinib belongs to a class of drugs called tyrosine kinase 2 (TYK2) inhibitors.
- TYK2 is an enzyme involved in the immune system's signaling pathways.
- By inhibiting TYK2, deucravacitinib helps reduce inflammation associated with psoriasis.
Dosage and Administration:
- Deucravacitinib comes in tablet form and is taken orally.
- It's important to note that it should not be combined with other strong immunosuppressant medications.
Approval and Availability:
- Deucravacitinib is a relatively new medication, having received approval in the US (September 2022) and Australia (December 2022).
- It's considered a first-in-class medication for its targeted approach to TYK2.
Important Considerations:
- While effective for moderate-to-severe plaque psoriasis, deucravacitinib can have side effects like increased risk of infections and malignancy due to its immunosuppressant nature.
- It may also elevate liver enzymes and triglycerides.
- Benefits typically take around 4 weeks to show and individual responses can vary.
- Due to its newness, limited information exists on its use outside of clinical trials.
If you have any further questions or are considering deucravacitinib for your psoriasis, it's crucial to consult a doctor to determine the best course of treatment for your specific situation.